Find Material Compliance Exposure Early
Identify inspection findings, systemic quality weaknesses, open remediation, unreliable data, vendor dependencies and unresolved regulatory commitments.
Back to Governance & Oversight
Independent GxP Risk Intelligence for Transactions and Strategic Decisions
Due Diligence & Compliance Risk Reviews
Independent assessment of GxP quality systems, regulatory exposure, operational controls and remediation liabilities for acquisitions, investments, licensing transactions, strategic partnerships, outsourcing decisions and post-transaction integration.
Service Overview
Evaluate Compliance Risk Before Committing Capital, Reputation or Control
GxP due diligence evaluates whether the target organization, product, program, platform or partner has reliable quality systems, defensible data and manageable compliance exposure.
Translate GxP Findings Into Transaction Impact
Assess how identified risks may influence valuation, timelines, continuity, regulatory strategy, integration cost and future investment.
Define Conditions, Priorities and Safeguards
Support leadership with risk-based recommendations for deal terms, remediation commitments, governance, integration and post-close oversight.
Common Due Diligence Risks
Quality Liabilities That May Be Hidden Behind Strong Commercial Potential
Commercial, scientific and financial due diligence may not fully reveal systemic GxP weaknesses that can later affect regulatory approval, integration effort and long-term value.
Incomplete Inspection and Audit History
Repeat findings, unresolved commitments, critical vendor issues or significant internal audit observations may be fragmented across functions.
Remediation Reported as Complete but Not Effective
CAPAs may be administratively closed without credible evidence that systemic causes were addressed or recurrence was prevented.
Quality Systems That Cannot Scale
Existing procedures, resources and governance may support current operations but fail under increased studies, products, sites or commercialization demands.
Undocumented Third-Party Dependency
Critical knowledge, systems, data and operations may depend on CROs, laboratories, manufacturers or technology vendors with weak oversight.
Due Diligence Services
Flexible Reviews for Transactions, Investments and Strategic Partnerships
Reviews can be delivered as focused red-flag assessments, comprehensive GxP due diligence or targeted evaluation of specific products, functions, sites, vendors or quality concerns.
Acquisition and Investment Due Diligence
Independent assessment of quality-system maturity, regulatory exposure and operational compliance risk before acquisition or investment.
- QMS maturity and governance
- Inspection and audit history
- Open deviations, CAPAs and commitments
- Product, study and data integrity risk
- Integration and valuation implications
Red-Flag Compliance Assessment
Focused review designed to identify potential deal-breaking or high-impact quality and regulatory concerns within a compressed transaction timeline.
- Material risk screening
- Critical document review
- Inspection and enforcement indicators
- Remediation and commitment exposure
- Executive red-flag summary
Clinical and Development Program Due Diligence
Evaluation of clinical quality, sponsor oversight, participant protection, trial data, TMF quality, vendors and inspection exposure.
- GCP and sponsor oversight
- Protocol and trial-compliance issues
- TMF and essential-record quality
- Data and computerized-system risk
- Clinical vendor dependencies
GMP and Supply Chain Risk Review
Assessment of manufacturing, laboratory, supplier, quality-system and product continuity risks affecting commercial or development assets.
- Manufacturing quality systems
- Laboratory and data reliability
- Deviation, OOS and CAPA performance
- Supplier and contract manufacturer risk
- Capacity, continuity and transfer exposure
Strategic Partnership and Licensing Review
Independent assessment of prospective partners before licensing, co-development, commercialization or long-term outsourcing.
- Quality capability and maturity
- Governance and responsibility allocation
- Inspection and compliance history
- Vendor and technology dependencies
- Agreement and oversight recommendations
Integration and Post-Close Quality Review
Translation of due diligence findings into controlled integration, remediation and quality-governance workstreams.
- Integration risk prioritization
- QMS harmonization strategy
- Remediation workstreams
- Governance and executive reporting
- Post-close effectiveness review
Confidential and risk-based review
Engagement scope, access, reporting and communication pathways should be agreed with transaction leadership and legal counsel. The review provides independent GxP quality and compliance insight and does not replace legal, financial, tax or intellectual-property due diligence.
Review Areas
GxP Areas Commonly Included in a Compliance Risk Review
The final scope is adapted to the transaction objective, target organization, product lifecycle, regulated activities, geography and available data-room evidence.
Quality Governance
- Quality leadership and independence
- Decision rights and escalation
- Management review
- Quality culture and accountability
- Executive risk visibility
Quality Management System
- Document control
- Training and qualification
- Deviation and CAPA
- Change control
- Quality risk management
Inspection and Audit History
- Regulatory inspection outcomes
- Internal and external audits
- Repeat observations
- Commitments and responses
- Closure and effectiveness evidence
Clinical Development
- Sponsor oversight
- Protocol compliance
- Monitoring and RBQM
- Investigator and site risk
- Participant protection
TMF and Clinical Records
- TMF completeness
- Record timeliness
- Document quality
- Vendor and system control
- Inspection reconstruction risk
Manufacturing and Laboratories
- Manufacturing controls
- Batch and laboratory records
- OOS and investigations
- Process and method validation
- Product quality trends
Pharmacovigilance
- Case processing
- Safety reporting
- Signal management
- Partner governance
- Inspection and compliance exposure
Data Integrity and Systems
- Data governance
- Computerized-system control
- Validation and intended use
- Access and audit trails
- Migration and retention risk
Vendor and Supply Chain Risk
- Critical vendor qualification
- Quality agreements
- Performance monitoring
- Single-source dependencies
- Continuity and transition risk
Review Process
From Transaction Objectives to Decision-Ready Compliance Risk Intelligence
The process combines targeted document review, management interviews, evidence testing and risk interpretation within the agreed transaction timeline.
Objective and Scope Definition
Clarify the transaction, target asset, intended use, decision timeline, materiality thresholds and priority GxP risk areas.
Data Room and Document Review
Review quality manuals, procedures, audits, inspections, CAPAs, metrics, vendor records, product information and regulatory evidence.
Management and SME Interviews
Challenge assumptions, clarify evidence, assess ownership and understand how quality systems operate in practice.
Risk and Materiality Analysis
Classify findings according to compliance significance, probability, operational impact, remediation effort and transaction relevance.
Executive Reporting
Present material risks, red flags, information gaps, financial and operational implications and recommended safeguards.
Integration and Follow-Up
Convert findings into pre-close conditions, post-close priorities, remediation governance and effectiveness-review plans.
Deliverables
Clear Outputs for Executives, Investors and Transaction Teams
Reporting is tailored to the transaction stage, audience, confidentiality requirements and level of technical detail needed for decision-making.
Red-Flag Risk Summary
- Material compliance concerns
- Potential deal blockers
- Immediate information gaps
- Regulatory exposure
- Priority recommendations
Due Diligence Report
- Executive summary
- Evidence-based findings
- Risk classification
- Business implications
- Recommended actions
Compliance Risk Heat Map
- Risk by system and function
- Severity and likelihood
- Regulatory significance
- Operational impact
- Remediation priority
Information Request List
- Missing critical evidence
- Follow-up documents
- Management clarifications
- Required supporting records
- Open diligence questions
Transaction Recommendations
- Pre-close conditions
- Representations and safeguards
- Governance recommendations
- Resource and cost considerations
- Post-close priorities
Integration Roadmap
- Immediate containment
- QMS integration priorities
- Remediation workstreams
- Owners and timelines
- Executive oversight
When This Service Is Most Valuable
Common Due Diligence and Compliance Risk Review Scenarios
Support can be tailored to early-stage screening, confirmatory due diligence, transaction negotiation or post-close integration.
Acquisition of a Life Sciences Company
The buyer needs an independent view of quality-system maturity, liabilities and integration requirements.
Biotechnology Investment
Investors require evaluation of clinical, data, vendor and QMS risk before funding.
Product or Asset Licensing
A clinical or commercial asset requires review of underlying development, manufacturing and compliance evidence.
Strategic Partnership
Prospective partners require assessment of quality capability, governance and shared regulatory exposure.
Critical Outsourcing Decision
A CRO, manufacturer, laboratory or technology provider will assume material GxP responsibilities.
Known Inspection History
The target has significant observations, commitments or remediation requiring independent evaluation.
Post-Close Integration
Due diligence findings must be converted into controlled quality and remediation workstreams.
Executive Compliance Concern
Leadership requires a confidential review before entering or continuing a strategic relationship.
Business Value
Make Better Transactions With a Clearer View of GxP Risk
Independent compliance due diligence helps decision-makers understand hidden liabilities, prioritize further investigation and establish safeguards before ownership or responsibility changes.
Earlier Identification of Material Risk
Detect systemic compliance weaknesses before they create unexpected remediation, delay or regulatory exposure.
More Defensible Investment Decisions
Connect quality and regulatory findings with valuation, deal conditions, governance and integration planning.
Faster Post-Close Prioritization
Enter integration with a structured view of immediate risks, remediation dependencies and required leadership oversight.
FAQ
Due Diligence and Compliance Risk Review Questions
Common questions from investors, executives, legal teams, private equity groups and life sciences organizations evaluating GxP risk.
Can you perform a rapid red-flag review?
Yes. A focused assessment can prioritize inspection history, material quality findings, remediation, data integrity, critical vendors and other potential transaction risks.
Can you review a full quality management system?
Yes. The review can cover governance, documentation, training, deviations, CAPA, change control, risk management, audits, vendor oversight, metrics and management review.
Can you support clinical asset due diligence?
Yes. The review can include sponsor oversight, protocol compliance, monitoring, RBQM, TMF quality, participant protection, vendors, systems and clinical data governance.
Can you assess remediation liabilities?
Yes. Open and completed remediation can be evaluated for scope, adequacy, implementation evidence, effectiveness, resource needs and residual risk.
Can you help after the transaction closes?
Yes. Support can include integration planning, QMS harmonization, remediation governance, quality leadership and effectiveness review.
Can the review be delivered remotely?
Yes. Data-room review, interviews, risk analysis, executive briefings and integration planning can be delivered remotely or through a hybrid model.